

Ocular Therapeutix Inc. (NASDAQ: OCUL): Highlights from the RBC Healthcare Conference

Sentiment Indicator : **positive**

Posted by Adnan Butt on Tuesday, February 24 2015, 8:28 PM ET

Key takeaways: Platform technology with multiple data readouts in 2015. Speaker Amar Sawhney, CEO

- OTX-DP Phase III study in post cataract surgery for inflammation and pain could read out in 1Q/ early 2Q:15.
- OTX-DP allergic conjunctivitis Phase III could start in 2015 and readout in Sep. / Oct.
- OTX-DP dry eye Phase II could read out in Sep. / Oct.
- OTX-TP glaucoma Phase IIb could read out in Sep. / Oct.
- Intravitreal anti-VEGF hydrogel depot. Things seem to be progressing but the timing of a partnership is yet to be determined. OCUL could also go its own way. A pre IND meeting with the FDA has been held and it seems the regulatory agency could be amenable to a back of the eye trial with anti-VEGF depot when OCUL reaches that stage.
- Technology appears more amenable than most in terms of its pliability to dose titrate and deliver over multiple periods.
- In our view, partnerships are likely.

Adnan Butt | Adnan.Butt@rbccm.com

[Click here](#) for disclosures for [Ocular Therapeutix Inc.](#), [Adnan Butt](#)

All rights reserved. This material may not be published, broadcast, rewritten or redistributed in any form. Please [click here](#) for legal restrictions and terms of use applicable to this site. Use of this site signifies your agreement to the terms of use.